reports
Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...
Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences...
Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...
Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum. Saliva is a complex fluid containing various enzy...
Meridian Bioscience Reports Third Quarter Fiscal 2021 Results
Meridian Bioscience Reports Third Quarter Fiscal 2021 Results CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submi...
Meridian Closes Acquisition of BreathTek® Business
Meridian Closes Acquisition of BreathTek® Business CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021. About Meridian Bioscience, Inc.Meridian is ...
Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H....
Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationshi...
Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Result...
Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021 CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in ...
Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2...
Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter CINCINNATI, July 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue for the third quarter of fiscal 2021 is expected to be approximately $63.5 million, below expectations. The Diagnostics segment performance was impacted negatively by recent supply chain issues with our LeadCare reagents that result...
Meridian Resubmits Application to FDA for Emergency Use Authorization ...
Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. On February 22, 2021, Meridian voluntarily withdrew its EUA application in order to conduct ad...
Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution ...
Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses CINCINNATI, June 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays. The Lyo-Ready™ RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruse...
Meridian Bioscience to Participate in the 41st Annual William Blair Gr...
Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Jack Kenny will also pre-record a presentation for the Jefferies Virtual Healthcare Conference which will be webcast on...
Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPC...
Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Plant Mix. This unique Mix is specifically designed to develop and manufacture multiplexed highly sensitive and economical molecular field-tests in agriculture biotechnology (AgBio). Increasing global food demand due to the growth in the human population accelerate...
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in S...
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021 CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-yearLife Science segment delivered net revenues of $53.3 million, up 139% year-over-yearDiagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% fro...
Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-R...
Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays. The Lyo-Ready™ DNA LAMP Mix is formulated for rapid, robust, and sensitive DNA amplification through nucleic acid strand displacement. The COVID-19...
Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Resul...
Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021 CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the liv...
Meridian Bioscience Announces FDA Submission for New Curian® Campy Ass...
Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s new Curian® Campy assay. This assay is one of many assays in the pipeline that expands the Curian® menu, continuing Meridian’s leadership in the gastrointestinal disease and lateral flow testing market. Curian® Campy, for use...
Meridian Launches its New Air-Dryable Mix for Crude Blood Samples
Meridian Launches its New Air-Dryable Mix for Crude Blood Samples CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, serum or plasma. The National Cancer Institute (NCI) and NHS England have predicted that tens of thousands of excess cancer deaths will occ...
Meridian Bioscience to Participate in H.C. Wainwright Global Life Scie...
Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on March 9, 2021. A link to access the pre-recorded presentation will be available in the Events & Presentations section of the Company...
Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV...
Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In subsequent communication with the FDA mid-morning on February 23, 2021, the FDA clarified that Meridian will no...
Meridian Bioscience Provides a Further Update on the Revogene® SARS-Co...
Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. Following the submission of Meridian’s written response to the FDA’s request for additional information on its Revogene® SARS-CoV-2 test o...
Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA...
Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In its ongoing discussion with the FDA, late in the day on Friday, February 12, 2021, the Company received further correspondence requesting additional ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.